Covestro’s new medical polycarbonate pushes the boundaries of heat resistance

Combines biocompatibility, heat-resistance, transparency and durability

EMA validates Type II variation application for enfortumab vedotin with pembrolizumab for treatment of bladder cancer

Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America

Strides receives USFDA approval for Pregabalin Capsules

The Pregabalin capsules has a market size of ~US$248 mn per IQVIA

Roche inaugurates new campus for Digital Centre of Excellence in Pune

The new campus has been designed as an employee-centred experience and ecosystem zone

Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union